| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1998.16.10.3257 |
| P698 | PubMed publication ID | 9779699 |
| P2093 | author name string | J Thomas | |
| U Jaeger | |||
| D Huhn | |||
| R Willemze | |||
| C Gisselbrecht | |||
| A Engert | |||
| D Crowther | |||
| J Lundin | |||
| H Dombret | |||
| R Marcus | |||
| H Mellstedt | |||
| A Osterborg | |||
| R Stahel | |||
| G Brittinger | |||
| E Rankin | |||
| A Epenetos | |||
| C Poynton | |||
| M Uppenkamp | |||
| N Nissen | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 3257-3263 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma | |
| P478 | volume | 16 |
| Q35147065 | Alemtuzumab |
| Q35022487 | Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? |
| Q34785883 | Alemtuzumab in T-cell malignancies |
| Q35206362 | Alemtuzumab therapy in B-cell lymphoproliferative disorders |
| Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
| Q35206351 | Antibodies for the treatment of diffuse large cell lymphoma. |
| Q80821330 | Antibody therapy of lymphoma |
| Q33924634 | Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues |
| Q24685049 | Biological response modifiers in cancer |
| Q34107861 | Biotherapy for lymphoma |
| Q42645688 | Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis |
| Q33340504 | Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders |
| Q44324002 | Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia |
| Q28548044 | Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity |
| Q94340486 | Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma |
| Q46812536 | Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network |
| Q30356145 | Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. |
| Q77378845 | Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma |
| Q43430617 | Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). |
| Q36490753 | Development of antibodies and chimeric molecules for cancer immunotherapy |
| Q40568145 | Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia |
| Q33956034 | First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab |
| Q34326110 | Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis |
| Q34785892 | Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. |
| Q33726963 | Immunopathogenesis and therapy of cutaneous T cell lymphoma |
| Q36586891 | Immunosuppressive preconditioning or induction regimens : evidence to date |
| Q40561962 | Innovative strategies in lymphoma therapy |
| Q73916896 | International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000 |
| Q35583232 | Management of the primary cutaneous lymphomas |
| Q35038955 | Monoclonal antibody therapy for B-cell lymphoma |
| Q35158950 | Monoclonal antibody therapy for lymphoma |
| Q35909297 | Monoclonal antibody therapy in lymphoid leukemias |
| Q81189032 | Monoclonal antibody therapy of cancer |
| Q34124133 | Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon? |
| Q53906324 | Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment. |
| Q35109116 | New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia |
| Q37701472 | New targets of therapy in T-cell lymphomas |
| Q34617307 | Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia |
| Q35558322 | Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma |
| Q35622810 | Peripheral T-cell lymphomas: diagnosis and management |
| Q35992515 | Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma |
| Q33434322 | Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma |
| Q33349421 | Phase II study of alemtuzumab in chronic lymphoproliferative disorders |
| Q37362699 | Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys |
| Q35158946 | Primary cutaneous lymphomas: a review with current treatment options |
| Q41924854 | Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review |
| Q33276657 | Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. |
| Q31166188 | Recombinant antibodies for the diagnosis and treatment of cancer |
| Q40750834 | Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients |
| Q41241909 | Rituximab for the treatment of patients with chronic lymphocytic leukemia |
| Q34386171 | Rituximab: perspective on single agent experience, and future directions in combination trials |
| Q36026719 | Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. |
| Q45201445 | Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy |
| Q37271928 | Systemic cancer therapy: evolution over the last 60 years |
| Q35164384 | Targeted therapies for the treatment of leukemia |
| Q50687660 | The 41st annual meeting of the American Society of Hematology. New Orleans, LA. December 3-7, 1999. |
| Q35163220 | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms |
| Q75216236 | Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy |
| Q35206348 | Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab |
| Q73888073 | Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab |
| Q35162055 | Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors |
Search more.